I am proud to continue working with the post-doctoral researchers of the Medway Centre for Pharmaceutical Sciences.

The Medway Centre for Pharmaceutical Sciences positions itself between discovery/biotech organisations and clinical research. Our goal is to use small quantities of chemical or biological APIs and advanced medicine design approaches to produce formulations for toxicology and exploratory clinical development. Most importantly, our expertise ensures that only formulations with commercial potential progress further in development. We design medicines that express optimum biology supported by advanced analytical chemistry and quality risk management processes. The Centre comprises senior University of Greenwich academics with industrial experience supported by industrialist consultants. We work to contemporary industrial time, quality and cost expectations, employing and teaching early career researchers to deliver value whilst gaining the skills and experience to become the next generation of scientific leaders in the pharmaceutical industry.

Member of the Expert Advisory Group for Pharmacy.

Representative of the pharmaceutical science community in Great Britain on the Assembly, the governance body comprising elected members from the three National Pharmacy Boards.

Senior management structure comprised the heads of: Chemical R&D, Analytical Research R&D, Materials Science, Oral Dosage Form R&D (US and UK); Parenteral Formulation R&D, the Quality by Design Program Office (US); Inhaled Dosage Form and Device Development, the Pfizer Green Chemistry Program (Sandwich and Cambridge in the UK). Initial headcount of 900 staff that was managed to 750. Main business/change management activities included: the closure and decommissioning of laboratory facilities at the Sittingbourne Research Centre; returning colleagues to Pfizer’s research campus in Sandwich; purchase and the capital development of laboratory facilities in Cambridge, UK to house the device engineering function of the Inhaled Dosage Form and Device Development Group; redevelopment of Sandwich Buildings to house the product development function of the Inhaled Dosage Form and Device Development Group including the design and building of novel open-plan laboratories.Managed the development and industrialization of: Maraviroc Tablets, DepoProvera Uniject, Genotropin MK VII Pen Injection System, Revatio Tablet and IV Injection, Slentrol, Cerenia.

Senior management structure comprised the heads of the Pharmaceutical, Chemical and Analytical Research and Development Groups on the five Pfizer Global R&D sites in Sandwich and Sittingbourne in Kent; Cambourne and Histon in Cambridge; Freiburg in Germany. 500 staff. Main business/change management activities included: consolidation of pharmaceutical sciences functions in Europe following the mergers of Pfizer, Warner Lambert and PharmaciaSite Head of the Freiburg Research Centre - completed the pharmaceutical development programs for Lyrica and Caduet and then closed the site; 130 colleagues were retired, out-placed or relocated to other Pfizer sites. Site Head of the Sittingbourne Research Centre. Restructured operations by relocating biotherapeutics development (protein and peptide drug development) to the Pfizer Global R&D site in St Louis, US, after the merger with Pharmacia. Existing staff were transitioned to work on inhaled drug delivery.Proposed the business case for, and led the $130 million purchase of Meridica from PA Consulting, and designed the integration process to create a two-site inhalation drug delivery centre in Histon and Cambourne in Cambridge. Managed the relocation of the Sutent development program from the Pharmacia Nerviano site in Milan and managed completion of the late-stage pharmaceutical development, technology transfer and commercial launch of the drug.

The management structure comprised the heads of: Formulation Design, Clinical Dosage Form Manufacturing and the Clinical Trials Pharmacy. Main business/change management activities included: restructuring the Clinical Trial Pharmacy to eliminate low skill packing jobs and to recruit talented pharmacy graduates to provide customer service links to the clinical development organisation; comissioned the sterile liquid and solid dosage form manufacturing areas at the Sandwich site; led the design, implementation and refinement of GMP systems in partnership with QA; recruited and trained over 40 skilled staff to operate the building to contemporary manufacturing standards. Initiated manufacturing and supply operations in 1999. in 2003 the MHRA (UK Government Medicines Inspectorate) validated that manufacturing and supply standards met GCP as defined under the new EU Clinical Trials Directive. The MHRA granted a full IMP Manufacturing Licence in 2004 after the Directive became operational in the UK. Scientific activities: Diflucan Capsule; Diflucan Tablet; Diflucan Injection. Discovered and developed Prodif (the fluconazole prodrug, fosfluconazole, for Japan); Dectomax and Dectomax Pour-on; Relpax Tablet; Vfend Tablet and Injection; Geodon IM; Viagra Tablet; Enablex Extended Release Tablets (licensed to Novartis at the Pharmacia acquisition); Revolution/Stronghold; Capitisol (sulphobutylether beta-cyclodextrin) an asset discovered by the University of Kansas/CyDex and used as an enabling excipient in Vfend and Geodon parenteral formulations.Established the Materials Science R&D. function to research into the solid-state characteristics of drugs including polymorphism and salt/solvate selection strategies.